How To Use CPT Code 0322U

CPT 0322U describes a specific proprietary laboratory analysis (PLA) test called NPDX ASD Test Panel III from Stemina Biomarker Discovery, NeuroPointDX division. This test uses liquid chromatography with tandem mass spectrometry (LC–MS/MS) to evaluate the level of metabolism-related chemical compounds in a plasma specimen. The test results are reported as either positive or negative for findings of a metabolic profile associated with autism spectrum disorder (ASD). In this article, we will cover the official description, procedure, qualifying circumstances, appropriate usage, documentation requirements, billing guidelines, historical information, and examples of CPT code 0322U.

1. What is CPT Code 0322U?

CPT 0322U is a proprietary laboratory analysis (PLA) code that applies to a specific test called NPDX ASD Test Panel III. This test is performed by Stemina Biomarker Discovery, NeuroPointDX division. It utilizes liquid chromatography with tandem mass spectrometry (LC–MS/MS) to evaluate the levels of specific chemical compounds in a plasma specimen. The test results are reported as either positive or negative for risk of metabolic subtypes associated with autism spectrum disorder (ASD).

2. Official Description

The official description of CPT code 0322U is: ‘Neurology (autism spectrum disorder [ASD]), quantitative measurements of 14 acyl carnitines and microbiome-derived metabolites, liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma, results reported as negative or positive for risk of metabolic subtypes associated with ASD.’

3. Procedure

1. The laboratory analyst uses liquid chromatography and mass spectrometry (LC–MS/MS) to evaluate a plasma specimen for 14 acyl carnitines and products of metabolism related to the microbiome.
2. LC–MS/MS is an automated laboratory platform that separates, identifies, and quantifies the level of specific chemical compounds in the specimen.
3. The test results are analyzed using an algorithm to determine the risk of metabolic subtypes associated with autism spectrum disorder (ASD).
4. The results are reported as either negative or positive for the risk of metabolic subtypes associated with ASD.

4. Qualifying circumstances

CPT code 0322U is applicable for patients undergoing the NPDX ASD Test Panel III from Stemina Biomarker Discovery, NeuroPointDX division. This test is specifically designed to evaluate the levels of 14 acyl carnitines and microbiome-derived metabolites in a plasma specimen. It is used to determine the risk of metabolic subtypes associated with autism spectrum disorder (ASD).

5. When to use CPT code 0322U

CPT code 0322U should be used when ordering the NPDX ASD Test Panel III from Stemina Biomarker Discovery, NeuroPointDX division. This test is specifically designed to evaluate the levels of 14 acyl carnitines and microbiome-derived metabolites in a plasma specimen and determine the risk of metabolic subtypes associated with autism spectrum disorder (ASD).

6. Documentation requirements

To support a claim for CPT code 0322U, the following documentation is required:

• Order for the NPDX ASD Test Panel III
• Date of service
• Results of the test indicating whether it is negative or positive for risk of metabolic subtypes associated with ASD

7. Billing guidelines

When billing for CPT code 0322U, ensure that the test is performed by Stemina Biomarker Discovery, NeuroPointDX division, and that the NPDX ASD Test Panel III is ordered. Report one unit of this code for a single specimen analyzed on a single date of service. Do not report this test using any other CPT code.

8. Historical information

CPT code 0322U was added to the Current Procedural Terminology system on April 1, 2022. There have been no updates to the code since its addition.

9. Examples

1. A patient undergoes the NPDX ASD Test Panel III to determine the risk of metabolic subtypes associated with autism spectrum disorder (ASD).
2. A physician orders the NPDX ASD Test Panel III for a child with suspected ASD to assess the metabolic profile.
3. A healthcare provider utilizes the NPDX ASD Test Panel III to aid in the diagnosis and management of a patient with autism spectrum disorder (ASD).
4. A parent requests the NPDX ASD Test Panel III for their child to gain insights into the metabolic aspects of autism spectrum disorder (ASD).
5. A researcher uses the NPDX ASD Test Panel III to study the metabolic subtypes associated with autism spectrum disorder (ASD).
6. A clinician orders the NPDX ASD Test Panel III for a patient with autism spectrum disorder (ASD) to guide personalized treatment decisions.
7. A child undergoes the NPDX ASD Test Panel III as part of a comprehensive evaluation for autism spectrum disorder (ASD).
8. A healthcare provider utilizes the NPDX ASD Test Panel III to monitor the metabolic profile of a patient with autism spectrum disorder (ASD) over time.
9. A parent opts for the NPDX ASD Test Panel III to gain a better understanding of the metabolic factors contributing to their child’s autism spectrum disorder (ASD).
10. A clinician orders the NPDX ASD Test Panel III to assess the metabolic subtypes associated with autism spectrum disorder (ASD) in a patient with atypical symptoms.